medigraphic.com
Instituto Nacional de Salud Pública

2003, Número 4

salud publica mex 2003; 45 (4)


Cartas al editor

Idioma: Inglés.
Referencias bibliográficas: 34
Paginas: 243-244
Archivo PDF: 126.90 Kb.


FRAGMENTO

Sin resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. World Health Organization. Control of Chagas disease. Report of a WHO expert committee. Ginebra: WHO, WHO Technical report series No. 811, 1991.

  2. Schofield CJ, Dias JC. The Southern Cone initiative against Chagas disease. Adv Parasitol 1999;42:1-27.

  3. Guzmán-Bracho C. Epidemiology of Chagas disease in Mexico: An update. Trend Parasit 2001;17:372-376.

  4. Dumonteil E. Update on Chagas disease in Mexico. Salud Publica Mex 1999;41:322-327.

  5. Secretaría de Salud. Norma técnica No 348, para la prevención y control de la tripanosomiasis en la atención primaria a la salud. México, DF: Diario Oficial de la Federación, 17 enero 1992.

  6. Brener Z. Chemotherapy of Trypanosoma cruzi infection. Arch Pharmacol Chemother 1975;13:13-44.

  7. Cancado JR. Long-term evaluation of etiological treatment of Chagas disease with

  8. benznidazole. Rev Inst Med Trop S Paulo 2002;44:29-37.

  9. Andrade SS, Guimaraes J. Randomized trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 1996;348(23):1407-1413.

  10. Sosa S, Segura EL, Mariano A, Velázquez E, Porcel BM, Yampotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas disease. Am J Trop Med Hyg 1998;59(4):526-529.

  11. Stoppani AOM. Quimioterapia de la enfermedad de Chagas. Medicina 1999;59(supl II):147-165.

  12. Reyes P, Vallejo M. Trypanocidal drugs for late stage, symptomatic Chagas disease (Cochrane Protocol). In: The Cochrane Library. Oxford: Update Software, 2003.

  13. Rodriguez-Coura J, De Abreu LL, Percy H, Wilcox F, Petana W. Estudo comparativo controlado com emprego de benznidazole, nifurtimox e placebo, na forma crónica da doenca de Chagas, em uma área de campo com trasmissao interrompida. I. Evaluacao preliminar. Rev Soc Bras Med Trop 1997;30:139-144.

  14. Viotti R, Vigliano C, Armenti H, Segura E. Treatment of chronic Chagas disease with benznidazole: Clinical and serological evolution of patients with long-term follow-up. Am Heart J 1994;127:151-162.

  15. 14.Fabro D, Arias E, Streiger M, Placenza M, Ingaramo M, Del Barco M et al. Evolutive behavior towards cardiomyopathy of treated (nifurtimox or benznidazole) and untreated chronic chagasic patients. Rev Inst Med Trop S Paulo 2000;42:99-109.

  16. Braga MS, Lauria-Pires L, Arganaraz ER, Nascemento RJ, Teixeira ARL. Persistent

  17. infection in chronic Chagas disease patients treated with anti-Trypanosoma cruzi nitroderivatives. Rev Inst Med Trop S Paulo 2000; 42: 157-161.

  18. Lauria-Pires L, Braga MS, Vexenat AC, Nitz N, Simoes-Barbosa A, Tinoco DL. Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives. Am J Trop Med Hyg 2000;63:111-118.

  19. World Health Organization. Control of Chagas disease. Report of a WHO expert committee. Ginebra: WHO, WHO Technical report series No. 811, 1991.

  20. Schofield CJ, Dias JC. The Southern Cone initiative against Chagas disease. Adv Parasitol 1999;42:1-27.

  21. Guzmán-Bracho C. Epidemiology of Chagas disease in Mexico: An update. Trend Parasit 2001;17:372-376.

  22. Dumonteil E. Update on Chagas disease in Mexico. Salud Publica Mex 1999;41:322-327.

  23. Secretaría de Salud. Norma técnica No 348, para la prevención y control de la tripanosomiasis en la atención primaria a la salud. México, DF: Diario Oficial de la Federación, 17 enero 1992.

  24. Brener Z. Chemotherapy of Trypanosoma cruzi infection. Arch Pharmacol Chemother 1975;13:13-44.

  25. Cancado JR. Long-term evaluation of etiological treatment of Chagas disease with benznidazole. Rev Inst Med Trop S Paulo 2002;44:29-37.

  26. Andrade SS, Guimaraes J. Randomized trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 1996;348(23):1407-1413.

  27. Sosa S, Segura EL, Mariano A, Velázquez E, Porcel BM, Yampotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas disease. Am J Trop Med Hyg 1998;59(4):526-529.

  28. Stoppani AOM. Quimioterapia de la enfermedad de Chagas. Medicina 1999;59(supl II):147-165.

  29. Reyes P, Vallejo M. Trypanocidal drugs for late stage, symptomatic Chagas disease (Cochrane Protocol). In: The Cochrane Library. Oxford: Update Software, 2003.

  30. Rodriguez-Coura J, De Abreu LL, Percy H, Wilcox F, Petana W. Estudo comparativo controlado com emprego de benznidazole, nifurtimox e placebo, na forma crónica da doenca de Chagas, em uma área de campo com trasmissao interrompida. I. Evaluacao preliminar. Rev Soc Bras Med Trop 1997;30:139-144.

  31. Viotti R, Vigliano C, Armenti H, Segura E. Treatment of chronic Chagas disease with benznidazole: Clinical and serological evolution of patients with long-term follow-up. Am Heart J 1994;127:151-162.

  32. 14.Fabro D, Arias E, Streiger M, Placenza M, Ingaramo M, Del Barco M et al. Evolutive behavior towards cardiomyopathy of treated (nifurtimox or benznidazole) and untreated chronic chagasic patients. Rev Inst Med Trop S Paulo 2000;42:99-109.

  33. Braga MS, Lauria-Pires L, Arganaraz ER, Nascemento RJ, Teixeira ARL. Persistent infection in chronic Chagas disease patients treated with anti-Trypanosoma cruzi nitroderivatives. Rev Inst Med Trop S Paulo 2000; 42: 157-161.

  34. Lauria-Pires L, Braga MS, Vexenat AC, Nitz N, Simoes-Barbosa A, Tinoco DL. Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives. Am J Trop Med Hyg 2000;63:111-118.




2020     |     www.medigraphic.com